Form 4: Hims & Hers CEO Sells $7.9M in Stock

Hims & Hers Health, Inc. CEO Andrew Dudum executed pre-planned sales of Class A Common Stock totaling 175,661 shares, alongside exercising 125,335 stock options.

Summary

• Andrew Dudum, the Chief Executive Officer, Director, and a 10% Owner of Hims & Hers Health, Inc. (HIMS), engaged in multiple transactions involving the company's Class A Common Stock on August 18, 2025.
• He acquired a total of 125,335 shares of Class A Common Stock through the exercise of stock options at an exercise price of $2.43 per share.
• Concurrently, he sold a total of 175,661 shares of Class A Common Stock in several direct transactions.
• The sales were executed at weighted average prices ranging from $44.9209 to $45.1373 per share, with individual sale prices varying between $44.65 and $45.43.
• All reported transactions were conducted pursuant to a Rule 10b5-1 trading plan that was adopted on August 28, 2024.
• Following these transactions, Dudum's direct beneficial ownership of Class A Common Stock is reported across several lines, including 89,521 shares, 106,522 shares, 197,855 shares, 156,188 shares, 106,188 shares, and 89,521 shares.
• His indirect beneficial ownership includes 142,592 shares held by the Trustee of Dudum Family Community Property Trust, 1,016,871 shares by the Trustee of Andrew Dudum 2015 Trust, 508,030 shares by the Trustee of AD 2022 GRAT, and significant holdings across other family trusts (AD 2021 GRAT, AD 2021 GRAT 2, AD 2022 GRAT 2, AD 2022 GRAT 3, AD 2023 GRAT, Dudum Family Heritage Trust, and AD 2025 GRAT).
• Remaining unexercised stock options total 51,007 and 648,063 shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While significant insider selling can sometimes be viewed negatively, the fact that these transactions were pre-planned under a Rule 10b5-1 plan mitigates concerns about immediate negative implications. It represents routine equity management by a long-term insider.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a systematic and pre-scheduled approach to managing equity rather than a reaction to immediate negative news.
• The exercise of stock options at a low price ($2.43) and subsequent sale at significantly higher market prices (around $45) demonstrates a substantial personal gain for the CEO.

Negatives

• Significant insider selling, even if pre-planned, can sometimes be perceived negatively by some investors as it reduces the insider's direct equity stake in the company.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• An annuity payment-in-kind of 26,461 shares of Class A Common Stock was made from the AD 2022 GRAT to the Andrew Dudum 2015 Trust dated July 2, 2015, both indirectly beneficially owned by the reporting person.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive could lead to minor concerns about management's conviction, though the Rule 10b5-1 plan mitigates this. The overall impact on the company's operations or strategic direction is minimal as it's a personal financial transaction.

Key Dates

Recommendation

The filing details routine insider transactions under a pre-arranged 10b5-1 plan, which are common for executives managing their equity. While there are significant sales, they are offset by option exercises and are not indicative of a change in the company's fundamental outlook or performance. Therefore, the filing itself does not provide new information that would warrant a change in investment thesis, suggesting a 'hold' recommendation based solely on this report.

Keywords

Hims & Hers Health, HIMS, Andrew Dudum, Insider Trading, SEC Form 4, Stock Sales, Option Exercise, Rule 10b5-1, CEO Stock, Beneficial Ownership